---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-062387"
form_type: "8-K"
ticker: "LRMR"
cik: "0001374690"
company_name: "Larimar Therapeutics, Inc."
filed_at: "2024-05-20T23:59:59+00:00"
generated_at: "2026-06-01T12:26:33.125131+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# FDA removes partial clinical hold on Larimar's nomlabofusp for Friedreich's Ataxia

## Summary
- FDA cleared Phase 2 data review; nomlabofusp generally well-tolerated with dose-dependent frataxin increases.
- OLE study continues at 25 mg; dose escalation to 50 mg planned after further frataxin PD characterization.
- Interim OLE data expected Q4 2024; BLA submission targeted for 2H 2025.
- In 50 mg cohort, all evaluable patients achieved skin frataxin >33% of healthy volunteer average at Day 14.

## SEC filing metadata
- accession: 0000950170-24-062387
- form_type: 8-K
- ticker: LRMR
- cik: 0001374690
- company_name: Larimar Therapeutics, Inc.
- filed_at: 2024-05-20T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374690/000095017024062387/0000950170-24-062387-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374690/000095017024062387/lrmr-20240520.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-062387
- JSON: https://secwatch.observer/filing/0000950170-24-062387.json
- Plain text: https://secwatch.observer/filing/0000950170-24-062387.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.